Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders
Aug 17, 2026, 00:33

Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders

Rupam Manna, Postdoctoral Student – DrNB Medical Oncology at National Board of Examinations, shared a post on X:

“CELMoDs: next-generation molecular-glue protein degraders.

By binding cereblon, CELMoDs redirect the CRL4–CRBN E3 ubiquitin ligase toward IKZF1 and IKZF3.

Their proteasomal degradation suppresses IRF4–MYC signalling, promotes myeloma-cell apoptosis and activates T and NK cells.

Key agents:

  • Iberdomide – first FDA-approved CELMoD
  • Mezigdomide – investigational in multiple myeloma
  • Golcadomide – investigational in lymphoma

Remember the major class toxicities: neutropenia, infections, anaemia and thrombocytopenia.”

Rupam Manna

Stay updated with Hemostasis Today.